Flatiron Health at ISPOR 2025
Booth #601
Flatiron is excited to attend and showcase our research at ISPOR 2025, validating exciting novel methodologies that will shape the future of evidence generation and health outcomes research in oncology.
Unlock critical evidence to accelerate access to cancer treatments worldwide
At Flatiron, we are unlocking HEOR evidence and insights to demonstrate the value of oncology treatments to stakeholders including payers, regulators, and providers. By leveraging our industry leading multinational oncology data assets from the US, UK, Germany, and Japan and unparalleled expertise, we’re generating a spectrum of tailored solutions configured for the specific evidence needs of life sciences companies.
Our research validates novel methodologies and introduces new approaches to health outcomes research—leveraging AI and machine learning to enhance the depth and broaden the applications of oncology real-world evidence.
Join our experts at booth #601 to discover how Flatiron is transforming the possibilities of oncology research, development, and access.
Featured session
Real-World Life-Cycle Evaluation for Precision Medicine: From Conceptualization to Successful Implementation
Wednesday, May 14 | 5:00-6:00PM ET
Room 710B
This session will explore how RWE is transforming precision medicine decision-making through a novel life-cycle health technology assessment (LC-HTA) framework. Featuring insights from the PREDiCT program in British Columbia, this session will showcase how RWE, when combined with early-phase trial data, can address uncertainty, demonstrate value over time, and inform regulatory and reimbursement decisions across borders. Learn how transportability of RWE enables international relevance, and engage in a live discussion on embedding LC-HTA into learning healthcare systems worldwide.
speaker
Blythe Adamson, PhD
Head, Outcomes Research & Evidence Generation, Flatiron Health
Featured solutions
Real-World Data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-World Evidence Services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your oncology portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Prospective Evidence Generation
We help sponsors generate prospective evidence through the pragmatic design and execution of, low-interventional, or observational studies enabled by our proprietary technology and centralized services.
Flatiron experts at ISPOR
Our research
Read more about our accepted research at this year’s conference.
Leveraging Machine Learning to Assess the Association of Rash and Survival in Patients With Advanced NSCLC
Author affiliations: Flatiron Health
This study uses machine learning to scalably extract real-world adverse events, assessing rash incidence and its link to survival in 5,600+ advanced NSCLC patients treated with EGFR TKIs, improving the accuracy and completeness of clinical data.
See this research
Date: Wednesday, May 14
Time: 10:30 AM - 1:30 PM
Poster Session 1
Poster Code: MSR24
Connect with a flatiron expert
Qianyu Yuan
Senior Research Scientist
Connect on LinkedIn
Using Regression Discontinuity in Time Design for Real-World Comparative Effectiveness: A Case Study for the Second-Line Use of Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Author affiliations: Flatiron Health, University of Colorado
This research demonstrates that advanced statistical methods like RDiT can help overcome some of the challenges of real-world data, providing more reliable real-world evidence on which treatments work best for patients.
See this research
Date: Thursday, May 15
Time: 10:30 - 1:30 PM
Poster Session 3
Poster Code: MSR87
Connect with a flatiron expert
Blythe Adamson
Head, Outcomes Research & Evidence Generation
Connect on LinkedIn
Patient Characteristics and Treatment Patterns in Extensive-Stage Small Cell Lung Cancer
Author affiliations: Flatiron Health, Tennessee Oncology, Jazz Pharmaceuticals
This study provides critical insights into how ES-SCLC patients are treated in real-world settings by analyzing treatment patterns and patient characteristics.
See this research
Date: Thursday, May 15
Time: 10:30 - 1:30 PM
Poster Session 3
Poster Code: HSD69
Connect with a flatiron expert
Taavy Miller
Senior Research Scientist
Connect on LinkedIn
Performance Assessment and Validation of Real-World Response Data Generated Using a Deep Learning-Based Natural Language Processing Model Across Multiple Solid Tumors
Author affiliations: Flatiron Health
This study validates the use of machine learning to extract real-world response from unstructured data in the EHR, offering a scalable and efficient method for generating high-quality oncology real-world data.
See this research
Date: Friday, May 16
Time: 9 - 11:30 AM
Poster Session 5
Poster Code: MSR142
Connect with a flatiron expert
Kelly Magee
Senior Clinical Director
Connect on LinkedIn
From Data to Decisions: The Role of Real-World Evidence in Recent Multiple Myeloma Drug Approvals in the US and EU
Author affiliations: Flatiron Health
Real-world evidence (RWE) is increasingly being incorporated into regulatory submissions for multiple myeloma treatments in the US and EU. This study highlights the acceptance of RWE by the FDA and EMA and underscores its potential to complement traditional clinical trial data.
See this research
Date: Friday, May 16
Time: 9 - 11:30 AM
Poster Session 5
Poster Code: HPR136
Connect with a flatiron expert
Angela Chen
Associate, Regulatory Strategy
Connect on LinkedIn
Advancing Breast Cancer Research in Japan Using EHR-Derived Real-World Data
Author affiliations: Flatiron Health
This study introduces the Flatiron Health Japan Breast Cancer dataset, a novel, de-identified real-world database derived from structured and unstructured data collected from routine oncology care and stored within the EHR and relevant hospital information systems in Japan.
See this research
Date: Friday, May 16
Time: 9 - 11:30 AM
Poster Session 5
Poster Code: RWD143
Connect with a flatiron expert
Harlan Pittell
Senior Research Scientist
Connect on LinkedIn
Augmenting Race and Ethnicity in a Real-World Oncology Cohort Using the Bayesian Improved Surname Geocoding Methodology
Author affiliations: Flatiron Health
This study assessed The Bayesian Improved Surname Geocoding (BISG) ability for imputing missing race/ethnicity data, “unlocking” patients with unknown race/ethnicity.
See this research
Date: Friday, May 16
Time: 9 - 11:30 AM
Poster Session 5
Poster Code: MSR136
Connect with a flatiron expert
Gene Ho
Research Scientist
Connect on LinkedIn
Analytical Approaches to Estimate Medication Persistence From Electronic Health Record Data: A Study of Tyrosine Kinase Inhibitors in Patients With Epidermal Growth Factor Receptor–Positive Advanced Non–Small Cell Lung Cancer
Author affiliations: Flatiron Health
This study highlights key differences between two common approaches for estimating treatment persistence—time-to-event (TTE) and non-TTE—demonstrating how methodological choices influence persistence estimates.
See this research
E-Poster Session: EP.12G
Poster Code: 01
Connect with a flatiron expert
Brooke Jarrett
Senior Research Scientist
Connect on LinkedIn
Looking for support in designing and executing HEOR studies with RWE?
Leverage Flatiron’s industry leading multinational oncology data assets and expertise to drive your real-world studies, including:
-
Evaluating comparative- and cost-effectiveness
-
Modeling long-term survival
-
Examining burden of illness
-
Analyzing treatment patterns
Reach out to learn more about how we partner to accelerate patient access to oncology therapies across the globe.